請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22577
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 顧記華 | |
dc.contributor.author | Pui-Kei Leong | en |
dc.contributor.author | 梁沛祺 | zh_TW |
dc.date.accessioned | 2021-06-08T04:21:18Z | - |
dc.date.copyright | 2010-09-13 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-07-13 | |
dc.identifier.citation | 1. Huang D. M., Guh J. H., Huang Y. T., Chueh S. C., Chiang P. C., and Teng C. M. Induction of mitotic arrest and apoptosis in human prostate cancer pc-3 cells by evodiamine. J Urol. 2005, 173:256-261.
2. Liao C. H., Pan S. L., Guh J. H., Chang Y. L., Pai H. C., Lin C. H., and Teng C. M. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis. 2005, 26:968-975. 3. DeLuca J. G., Moree B., Hickey J. M., Kilmartin J. V., and Salmon E. D. hNuf2 inhibition blocks stable kinetochore-microtubule attachment and induces mitotic cell death in HeLa cells. J Cell Biol. 2002, 159:549-555. 4. Woods C. M., Zhu J., McQueney P. A., Bollag D., and Lazarides E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1995, 1:506-526. 5. Zemskova M., Sahakian E., Bashkirova S., and Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008, 283:20635-20644. 6. Risinger A. L., Giles F. J., and Mooberry S. L. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009, 35:255-261. 7. van der Vaart B., Akhmanova A., and Straube A. Regulation of microtubule dynamic instability. Biochem Soc Trans. 2009, 37:1007-1013. 8. Wittmann T., Hyman A., and Desai A. The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol. 2001, 3:E28-34. 9. Morris P. G. and Fornier M. N. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res. 2008, 14:7167-7172. 10. Drukman S. and Kavallaris M. Microtubule alterations and resistance to tubulin-binding agents (review). Int J Oncol. 2002, 21:621-628. 11. Orr G. A., Verdier-Pinard P., McDaid H., and Horwitz S. B. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003, 22:7280-7295. 12. Hotchkiss R. S., Strasser A., McDunn J. E., and Swanson P. E. Cell death. N Engl J Med. 2009, 361:1570-1583. 13. Kerr J. F., Wyllie A. H., and Currie A. R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972, 26:239-257. 14. Russo A., Terrasi M., Agnese V., Santini D., and Bazan V. Apoptosis: a relevant tool for anticancer therapy. Ann Oncol. 2006, 17 Suppl 7:vii115-123. 15. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K. J., Debatin K. M., Krammer P. H., and Peter M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687. 16. Barnhart B. C., Alappat E. C., and Peter M. E. The CD95 type I/type II model. Semin Immunol. 2003, 15:185-193. 17. Burz C., Berindan-Neagoe I., Balacescu O., and Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009, 48:811-821. 18. Harding H. P., Calfon M., Urano F., Novoa I., and Ron D. Transcriptional and translational control in the Mammalian unfolded protein response. Annu Rev Cell Dev Biol. 2002, 18:575-599. 19. Zhang K. and Kaufman R. J. Signaling the unfolded protein response from the endoplasmic reticulum. J Biol Chem. 2004, 279:25935-25938. 20. Schroder M. and Kaufman R. J. The mammalian unfolded protein response. Annu Rev Biochem. 2005, 74:739-789. 21. Chowdhury I., Tharakan B., and Bhat G. K. Caspases - an update. Comp Biochem Physiol B Biochem Mol Biol. 2008, 151:10-27. 22. Hochegger H., Takeda S., and Hunt T. Cyclin-dependent kinases and cell-cycle transitions: does one fit all? Nat Rev Mol Cell Biol. 2008, 9:910-916. 23. Lindqvist A., Rodriguez-Bravo V., and Medema R. H. The decision to enter mitosis: feedback and redundancy in the mitotic entry network. J Cell Biol. 2009, 185:193-202. 24. Perry J. A. and Kornbluth S. Cdc25 and Wee1: analogous opposites? Cell Div. 2007, 2:12. 25. Malumbres M. and Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005, 30:630-641. 26. Vakifahmetoglu H., Olsson M., and Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ. 2008, 15:1153-1162. 27. Blagosklonny M. V. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle. 2007, 6:70-74. 28. Hyzy M., Bozko P., Konopa J., and Skladanowski A. Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol. 2005, 69:801-809. 29. Castedo M., Perfettini J. L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004, 23:2825-2837. 30. Hibi M., Lin A., Smeal T., Minden A., and Karin M. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 1993, 7:2135-2148. 31. Derijard B., Hibi M., Wu I. H., Barrett T., Su B., Deng T., Karin M., and Davis R. J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994, 76:1025-1037. 32. Dhanasekaran D. N. and Reddy E. P. JNK signaling in apoptosis. Oncogene. 2008, 27:6245-6251. 33. Lin A. and Dibling B. The true face of JNK activation in apoptosis. Aging Cell. 2002, 1:112-116. 34. Liu J. and Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 2005, 15:36-42. 35. Widmann C., Gerwins P., Johnson N. L., Jarpe M. B., and Johnson G. L. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol Cell Biol. 1998, 18:2416-2429. 36. Fan M. and Chambers T. C. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat. 2001, 4:253-267. 37. Tournier C., Hess P., Yang D. D., Xu J., Turner T. K., Nimnual A., Bar-Sagi D., Jones S. N., Flavell R. A., and Davis R. J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science. 2000, 288:870-874. 38. Deng Y., Ren X., Yang L., Lin Y., and Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell. 2003, 115:61-70. 39. Roos W. P. and Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006, 12:440-450. 40. Montecucco A. and Biamonti G. Cellular response to etoposide treatment. Cancer Lett. 2007, 252:9-18. 41. Kurz E. U. and Lees-Miller S. P. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst). 2004, 3:889-900. 42. Uziel T., Lerenthal Y., Moyal L., Andegeko Y., Mittelman L., and Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J. 2003, 22:5612-5621. 43. Zou L. and Elledge S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003, 300:1542-1548. 44. Zou L., Liu D., and Elledge S. J. Replication protein A-mediated recruitment and activation of Rad17 complexes. Proc Natl Acad Sci U S A. 2003, 100:13827-13832. 45. Lobrich M. and Jeggo P. A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer. 2007, 7:861-869. 46. Norbury C. J. and Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004, 23:2797-2808. 47. Shrivastav M., De Haro L. P., and Nickoloff J. A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008, 18:134-147. 48. Cuypers H. T., Selten G., Quint W., Zijlstra M., Maandag E. R., Boelens W., van Wezenbeek P., Melief C., and Berns A. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984, 37:141-150. 49. Amaravadi R. and Thompson C. B. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest. 2005, 115:2618-2624. 50. Shah N., Pang B., Yeoh K. G., Thorn S., Chen C. S., Lilly M. B., and Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer. 2008, 44:2144-2151. 51. Wang Z., Bhattacharya N., Weaver M., Petersen K., Meyer M., Gapter L., and Magnuson N. S. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci. 2001, 2:167-179. 52. Saris C. J., Domen J., and Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991, 10:655-664. 53. Xie Y., Xu K., Dai B., Guo Z., Jiang T., Chen H., and Qiu Y. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene. 2006, 25:70-78. 54. Bachmann M. and Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005, 37:726-730. 55. Kumar A., Mandiyan V., Suzuki Y., Zhang C., Rice J., Tsai J., Artis D. R., Ibrahim P., and Bremer R. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol. 2005, 348:183-193. 56. Jacobs M. D., Black J., Futer O., Swenson L., Hare B., Fleming M., and Saxena K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem. 2005, 280:13728-13734. 57. Pogacic V., Bullock A. N., Fedorov O., Filippakopoulos P., Gasser C., Biondi A., Meyer-Monard S., Knapp S., and Schwaller J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007, 67:6916-6924. 58. Fedorov O., Marsden B., Pogacic V., Rellos P., Muller S., Bullock A. N., Schwaller J., Sundstrom M., and Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007, 104:20523-20528. 59. Holder S., Zemskova M., Zhang C., Tabrizizad M., Bremer R., Neidigh J. W., and Lilly M. B. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther. 2007, 6:163-172. 60. Xu Y., Zhang T., Tang H., Zhang S., Liu M., Ren D., and Niu Y. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J Surg Oncol. 2005, 92:326-330. 61. He H. C., Bi X. C., Zheng Z. W., Dai Q. S., Han Z. D., Liang Y. X., Ye Y. K., Zeng G. H., Zhu G., and Zhong W. D. Real-time quantitative RT-PCR assessment of PIM-1 and hK2 mRNA expression in benign prostate hyperplasia and prostate cancer. Med Oncol. 2009, 26:303-308. 62. Silverman J. A. Multidrug-resistance transporters. Pharm Biotechnol. 1999, 12:353-386. 63. Wils P., Phung-Ba V., Warnery A., Lechardeur D., Raeissi S., Hidalgo I. J., and Scherman D. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994, 48:1528-1530. 64. Ling Y. H., Tornos C., and Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem. 1998, 273:18984-18991. 65. Wang L. G., Liu X. M., Kreis W., and Budman D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999, 44:355-361. 66. Poruchynsky M. S., Wang E. E., Rudin C. M., Blagosklonny M. V., and Fojo T. Bcl-xL is phosphorylated in malignant cells following microtubule disruption. Cancer Res. 1998, 58:3331-3338. 67. Moulding D. A., Giles R. V., Spiller D. G., White M. R., Tidd D. M., and Edwards S. W. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood. 2000, 96:1756-1763. 68. Kobayashi S., Lee S. H., Meng X. W., Mott J. L., Bronk S. F., Werneburg N. W., Craig R. W., Kaufmann S. H., and Gores G. J. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem. 2007, 282:18407-18417. 69. Brooks C. and Dong Z. Regulation of mitochondrial morphological dynamics during apoptosis by Bcl-2 family proteins: a key in Bak? Cell Cycle. 2007, 6:3043-3047. 70. Srivastava R. K., Mi Q. S., Hardwick J. M., and Longo D. L. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A. 1999, 96:3775-3780. 71. Mollinedo F. and Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 2003, 8:413-450. 72. Ip Y. T. and Davis R. J. Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. Curr Opin Cell Biol. 1998, 10:205-219. 73. Roth B. J., Yeap B. Y., Wilding G., Kasimis B., McLeod D., and Loehrer P. J. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993, 72:2457-2460. 74. Burchert A., Wang Y., Cai D., von Bubnoff N., Paschka P., Muller-Brusselbach S., Ottmann O. G., Duyster J., Hochhaus A., and Neubauer A. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia. 2005, 19:1774-1782. 75. Xia Z., Knaak C., Ma J., Beharry Z. M., McInnes C., Wang W., Kraft A. S., and Smith C. D. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009, 52:74-86. 76. Beharry Z., Zemskova M., Mahajan S., Zhang F., Ma J., Xia Z., Lilly M., Smith C. D., and Kraft A. S. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009, 8:1473-1483. 77. Cheney I. W., Yan S., Appleby T., Walker H., Vo T., Yao N., Hamatake R., Hong Z., and Wu J. Z. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett. 2007, 17:1679-1683. 78. Xie Y., Xu K., Linn D. E., Yang X., Guo Z., Shimelis H., Nakanishi T., Ross D. D., Chen H., Fazli L., Gleave M. E., and Qiu Y. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2008, 283:3349-3356. 79. Borillo G. A., Mason M., Quijada P., Volkers M., Cottage C., McGregor M., Din S., Fischer K., Gude N., Avitabile D., Barlow S., Alvarez R., Truffa S., Whittaker R., Glassy M. S., Gustafsson A. B., Miyamoto S., Glembotski C. C., Gottlieb R. A., Brown J. H., and Sussman M. A. Pim-1 kinase protects mitochondrial integrity in cardiomyocytes. Circ Res. 2010, 106:1265-1274. 80. Tanaka T., Huang X., Halicka H. D., Zhao H., Traganos F., Albino A. P., Dai W., and Darzynkiewicz Z. Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents. Cytometry A. 2007, 71:648-661. 81. Celeste A., Petersen S., Romanienko P. J., Fernandez-Capetillo O., Chen H. T., Sedelnikova O. A., Reina-San-Martin B., Coppola V., Meffre E., Difilippantonio M. J., Redon C., Pilch D. R., Olaru A., Eckhaus M., Camerini-Otero R. D., Tessarollo L., Livak F., Manova K., Bonner W. M., Nussenzweig M. C., and Nussenzweig A. Genomic instability in mice lacking histone H2AX. Science. 2002, 296:922-927. 82. Baure J., Izadi A., Suarez V., Giedzinski E., Cleaver J. E., Fike J. R., and Limoli C. L. Histone H2AX phosphorylation in response to changes in chromatin structure induced by altered osmolarity. Mutagenesis. 2009, 24:161-167. 83. Sluss H. K. and Davis R. J. H2AX is a target of the JNK signaling pathway that is required for apoptotic DNA fragmentation. Mol Cell. 2006, 23:152-153. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/22577 | - |
dc.description.abstract | Evodiamine為由植物吳茱萸(Evodiae Fructus)分離之主成分,有研究指出其可抑制多種癌細胞的生長活性。我們實驗室獲得一系列Evodiamine衍生物,並利用SRB assay測試其抗癌活性,發現當中有很多的衍生物都比Evodiamine強10倍,其中Evo00825在眾多的衍生物中最為突出。其可抑制多種癌細胞的生長活性,包括攝護腺癌細胞(PC-3、DU145與LNCaP)、肝癌細胞(Hep3B)、乳癌細胞(MCF-7)及大量表現P-glycoprotein的乳癌細胞(NCI/ADR-RES),其IC50約介於50至210 nM之間。由於Evo00825也抑制了NCI/ADR-RES的細胞生長,故此化合物並非為P-glycoprotein的受質。隨著時間的增加,Evo00825會造成PC-3細胞產生G2/M期停滯,並於長時間下引起細胞凋亡。根據in vitro與in vivo微小管聚合試驗與免疫螢光試驗顯示,Evo00825造成PC-3細胞不正常有絲分裂紡錘體的產生。此化合物增加cyclin B1與MPM2的表現量,使Cdk1之Thr161位置與Cdc25C之Thr48位置磷酸化,同時也造成MAP4的磷酸化,這些結果顯示Evo00825使細胞停滯於有絲分裂期。此外,與粒線體相關的訊息傳遞也受到Evo00825之影響,包括Bcl-2與Bcl-xL之磷酸化、caspase-9與-3之活化及poly(ADP-ribose) polymerase (PARP)之斷裂。另外JNK抑制劑SP600125可顯著的抑制Bcl-2與Bcl-xL的磷酸化及caspase-3和PARP的斷裂,同時也阻止細胞進入有絲分裂期並降低Evo0025引起的細胞死亡。總結來說,這些結果顯示經由Evo00825引起的抗生長活性與細胞凋亡作用,是透過抑制微小管聚合、引發JNK相關的路徑,使細胞停滯在有絲分裂期及引起微小管調控之細胞凋亡途徑達到細胞死亡。
Pim-1為一種serine/threonine kinase的oncogene,負責參與細胞生長、增生與分化等多種功能,並對於攝護腺癌尤其是荷爾蒙不依賴型攝護腺癌的發生過程有密切的關係。第二篇主要探討Pim-1在微小管結合藥物於荷爾蒙不依賴型攝護腺癌細胞引發的細胞凋亡所扮演的角色,利用多種微小管結合藥物包括paclitaxel、vincristine、colchicine、evodiamine與Evo00825進行探討,結果顯示這些微小管結合藥物可透過活化轉錄因子STAT3引起Pim-1表現量的增加,利用Pim-1 siRNA可以使細胞對微小管結合藥物所產生的細胞毒性更為敏感並降低藥物所引起的G2/M期累積。根據免疫螢光試驗顯示Pim-1與微小管聚集在一起,但由微小管聚合試驗發現抑制Pim-1的表現並沒有改變微小管結合藥物所引起的微小管動態平衡。同時抑制Pim-1會減緩DNA damage sensor中ATM與DNA-PKcs的活化,但卻引起DNA雙股斷裂指標蛋白H2A.X之Ser139位置磷酸化的增加,有趣的是在comet assay中並沒有發現comet tail的增加,由此證實抑制Pim-1後細胞對於paclitaxel所增加的細胞凋亡與DNA損傷並沒有直接的關係。另一方面,根據免疫螢光試驗顯示抑制Pim-1會減少DNA-PKcs與Ku蛋白的結合,導致non-homologous end-joining (NHEJ)途徑受到抑制。總結來說,這些結果顯示Pim-1 knockdown可以抑制DNA-PKcs所參與的NHEJ途徑,使染色質保護受阻造成H2A.X的磷酸化,同樣也顯示Pim-1可以作為提高抗癌藥物活性的潛力標靶。 | zh_TW |
dc.description.abstract | Evodiamine, a bioactive component derived from Evodiae Fructus, displays anticancer activity against a variety of types of human cancers. According to the anticancer potential of evodiamine, we obtained a series of evodiamine derivatives and determined their anticancer activities. After a screening test on cell proliferation by sulforhodamine B assay, we found several active derivatives demonstrating more than ten-fold potency compared with the parent compound. Accordingly, we studied the anticancer mechanism and evaluate the potential of Evo00825, which stood out from these derivatives. Evo00825 inhibited cell proliferation of various cancer cell lines, including prostate cancer PC-3, DU-145 and LNCaP, hepatocellular carcinoma Hep3B, breast cancer MCF-7 and P-glycoprotein (P-gp)-overexpressed NCI/ADR-RES cells with IC50 values ranging from 84 to 210 nM. The data also indicated that Evo00825 was a poor substrate for P-gp, since over-expressed P-gp did not blunt Evo00825-mediated effect. The cytofluorometric analysis showed that Evo00825 induced G2/M arrest of the cell cycle in a time-dependent manner, followed by a sequential increase of hypodiploid phase (apoptosis). Evo00825 inhibited microtubule assembly in both in vitro turbidity assay and in vivo microtubule spin-down experiment. Immunochemical examination showed that Evo00825 caused abnormal mitotic spindles in PC-3 cells. This compound also activated the up-regulation of cyclin B1 expression, Cdk1 phosphorylation at Thr161, Cdc25C phosphoryltaion at Thr48 as well as MAP4 phosphorylation and elevation of MPM-2 levels. These data indicated the occurrence of mitotic arrest to Evo00825 action. Moreover, several mitochondria-mediated intrinsic pathways were activated by Evo00825, including phosphorylation of Bcl-2 and Bcl-xL, activation of caspase-9 and -3, and cleavage of poly(ADP-ribose) polymerase (PARP). The JNK inhibitor, SP600125, significantly blocked Evo00825-induced Bcl-2 and Bcl-xL phosphorylation, caspase-3 activity and PARP cleavage. It also abolished the mitotic arrest and rescued the apoptotic cell death caused by Evo00825. In summary, the data suggest that Evo00825 induces anti-proliferative and apoptotic effects in cancer cells through the inhibition of tubulin polymerization and stimulation of JNK activity, resulting in the induction of mitotic arrest and mitochondria-mediated apoptotic pathways and, ultimately, leading to apoptosis of cancer cells. The data also provide evidence supporting the further development of evodiamine derivatives.
Pim-1, a serine/threonine kinase functions as an oncogene, has diverse biological roles in cell survival, proliferation and differentiation and has been implicated in prostate cancer progression, particularly in hormone-refractory prostate cancers. In this study, we tried to identify the role of Pim-1 in microtubule-binding agent-mediated apoptosis in human hormone-refractory prostate cancer cells. Several microtubule-binding agents were used including paclitaxel, vincristine, colchicine and evodiamine. These agents activated STAT3 phosphorylation and its transcriptional activity, leading to up-regulation of Pim-1 expression. The knockdown of Pim-1 expression by siRNA transfection technique sensitized cells to the cytotoxic effects and reduced accumulation of G2/M phase of the cell-cycle caused by these microtubule-binding agents. Confocal microscopic examination showed that Pim-1 was co-localized with tubulin. However, the tubulin polymerization assay revealed that the knockdown of Pim-1 did not change the tubulin/microtubule dynamics under the treatment of microtubule-binding agents. The knockdown of Pim-1 delayed and reduced the activation of ATM and DNA-PKcs, a DNA damage sensor, but showed the activation of the phosphorylation of H2A.X at Ser139, a DNA double-stranded break marker, in an ATM-independent manner. Notably, the comet assay did not show an increase of comet tail suggesting that the sensitization of paclitaxel-mediated apoptosis by Pim-1 knockdown was not through the direct effect on DNA damage. Moreover, confocal microscopic examination showed that Pim-1 knockdown reduced the binding of DNA-PKcs and Ku protein, resulting in the inhibition of NHEJ pathway. In summary, we suggest that Pim-1 knockdown potentiates paclitaxel-induced H2A.X phosphorylation through the inhibition of Pim-1-involved and DNA-PKcs-signaled NHEJ pathway, leading to the blockade of rescuing chromatin defects. The data also reveal that Pim-1 kinase serves as a potential target to enhance the anticancer activity of therapeutic drugs. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T04:21:18Z (GMT). No. of bitstreams: 1 ntu-99-R97423010-1.pdf: 2770411 bytes, checksum: d9b33903881156e44334dedf60b8cd36 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 縮寫表 I
中文摘要 II 英文摘要 IV 背景 1 實驗材料與方法 11 附圖 18 第一章、探討Evo00825對人類荷爾蒙不依賴型前列腺癌細胞之作用機轉 24 結果 25 討論 29 結論 33 圖 34 第二章、探討Pim-1蛋白在微小管結合劑引發的細胞凋亡中的所扮演的角色 43 結果 44 討論 47 結論 50 圖 51 參考文獻 59 | |
dc.language.iso | zh-TW | |
dc.title | Part I:探討Evo00825對人類荷爾蒙不依賴型前列腺癌細胞之作用機轉;Part II:探討Pim-1在微小管作用劑引發的細胞凋亡中所扮演的角色 | zh_TW |
dc.title | Part I: Study of anticancer mechanism of Evo00825 in human hormone-refractory prostate cancer cells;Part II: Study of the role of Pim-1 in microtubule-binding agents mediated apoptosis in human hormone-refractory prostate cancer cells | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 蕭哲志,黃聰龍,楊家榮 | |
dc.subject.keyword | 細胞凋亡,細胞週期停止於G2/M時期,抗微管蛋白作用,pim-1蛋白, | zh_TW |
dc.subject.keyword | apoptosis,G2/M arrest,anti-microtubule,pim-1, | en |
dc.relation.page | 65 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2010-07-13 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 2.71 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。